PT -期刊文章盟以斯帖Wittermans盟Stefan M.T. Vestjens AU -西蒙尼·贝拉Spoorenberg盟——威廉·l·勃洛克盟——简·c·格拉特案的裁决AU -罗伯·詹森盟蒙古包t . Rijkers AU -弗兰克W.J.M. Smeenk AU - g .保罗Voorn盟Ewoudt M.W. van de加尔达盟-威廉简·w·Bos盟Santeon-CAP研究小组TI -辅助治疗口服地塞米松non-ICU:社区获得性肺炎患者住院:一项随机临床试验AID - 10.1185 /13993003.02535-2020 DP - 2021年8月1日TA -欧洲呼吸杂志PG - 2002535 VI - 58 IP -2 4099 - //www.qdcxjkg.com/content/58/2/2002535.short 4100 - //www.qdcxjkg.com/content/58/2/2002535.full SO - Eur Respir J2021年8月1日;58 AB -背景辅助静脉注射皮质类固醇治疗已被证明可缩短社区获得性肺炎(CAP)住院成人的住院时间(LOS)。我们旨在评估口服地塞米松对LOS的影响，以及这种影响是否与疾病严重程度相关。在这项多中心、分层随机、双盲、安慰剂对照试验中，免疫功能正常的CAP成年人被随机分配(1:1比例)接受口服地塞米松(6mg，每日1次)或安慰剂，在荷兰的4家教学医院治疗4天。随机分组(四组)按CAP严重程度分层(肺炎严重指数I-III和IV-V级)。主要结局为LOS。在2012年12月至2018年11月期间，401名患者随机接受地塞米松(n=203)或安慰剂(n=198)。地塞米松组的中位LOS(4.5天，95% CI 4.0-5.0天)短于安慰剂组(5.0天，95% CI 4.6-5.4天;p = 0.033)。 Within both CAP severity subgroups, differences in LOS between treatment groups were not statistically significant. The secondary ICU admission rate was lower in the dexamethasone arm (5 (3%) versus 14 (7%); p=0.030); 30-day mortality did not differ between groups. In the dexamethasone group the rate of hospital readmission tended to be higher (20 (10%) versus 9 (5%); p=0.051) and hyperglycaemia (14 (7%) versus 1 (1%); p=0.001) was more prevalent.Conclusion Oral dexamethasone reduced LOS and ICU admission rate in adults hospitalised with CAP. It remains unclear for which patients the risk–benefit ratio is optimal.Adjunctive treatment with oral dexamethasone in adults hospitalised with community-acquired pneumonia (CAP) reduced length of stay and ICU admission rate. However, it remains unclear for which CAP subgroup the risk–benefit ratio is optimal. https://bit.ly/35tXfPX